You are here

Biologics Licence Application Filed for Arilvax, Yellow Fever Vaccine

Cambridge, UK and Cambridge, Massachusetts – 12 December 2003 – Acambis plc (“Acambis') (LSE: ACM, NASDAQ: ACAM) announces that it has filed a Biologics License Application (“BLA') with the CBER vaccine division of the US Food and Drug Administration (“FDA') to seek registration in the US of its ARILVAXTM vaccine to prevent yellow fever.

Acambis recently completed a Phase III paediatric trial of ARILVAXTM, which provided additional data to supplement that generated from two previous Phase III adult trials.

ARILVAXTM is a live, attenuated vaccine to prevent yellow fever. It is already registered in 10 countries, including the UK, and Acambis has the rights to market the vaccine in the US. Rights outside of the US are owned by the vaccine's manufacturer, Chiron Vaccines, part of California-based Chiron Corporation.

Dr John Brown, Chief Executive Officer of Acambis, commented:

“This submission marks a major achievement for Acambis, not only because this is our first ever BLA but also because it is the first time a BLA has been submitted electronically to the CBER vaccine division of the FDA. It is another significant milestone in our plan to establish a travel vaccines franchise in North America.

Source: Acambis

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs